OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cortes Discusses TKI Cessation in CML

March 3rd 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the success of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML).

Dr. Graff on the Use of Abiraterone in Metastatic Prostate Cancer

March 3rd 2018

Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).

Dr. Tyson on Rationale For Neoadjuvant Chemotherapy in Bladder Cancer

March 3rd 2018

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Dr. Coutre Discusses Blinatumomab in MRD-Positive ALL

March 3rd 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses the role of blinatumomab (Blincyto) for patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL).

Dr. Bekaii-Saab Discusses PEGPH20 in Pancreatic Adenocarcinoma

March 2nd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

Dr. Donnellan Reflects on FDA Approvals in Acute Leukemia

March 2nd 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

March 2nd 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer

March 2nd 2018

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Dr. Ho on How Molecular Subtypes Affect Sequencing

March 2nd 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Dr. Skarbnik on Combination Strategies of Immunotherapy in Hematologic Malignancies

March 2nd 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses combination strategies with immunotherapy for patients with hematologic malignancies.

Dr. Goldberg on Precision Medicine in Hematologic Malignancies

March 2nd 2018

Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

Dr. Rugo Discusses Advancements With Biosimilars

March 2nd 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent advancements with biosimilars.

Dr. Perl Discusses the Impact of the ELIANA Trial

March 1st 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC

March 1st 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

Dr. Freedland on Diet and Lifestyle Interventions in Patients With Prostate Cancer

March 1st 2018

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Dr. Daskivich on Imaging Modalities in Prostate Cancer

March 1st 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

Dr. Figlin on the Safety Profile of Immuno-Oncology Agents in Kidney Cancer

March 1st 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.

Dr. Posadas on the Use of Circulating Tumor Cells in mCRPC

March 1st 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

March 1st 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Dr. Luke Discusses Noncutaneous Melanoma

March 1st 2018

Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.